The overall goal of the Penn/Wistar Skin Cancer Development Research Program (DRP) is to advance high quality research, foster new ideas, and to move research studies from pilot to project status. A second goal of the DRP is to create opportunities for the career development of junior faculty or senior investigators who are interested in transitioning into skin cancer research.
Specific aim 1 : To attract, select and fund the most outstanding proposals with significant potential to benefit the Skin Cancer SPORE and translational skin cancer research.
Specific aim 2 : To support and integrate the selected pilot projects into the SPORE program with established processes to review and monitor progress. Women and underrepresented minorities will be strongly encouraged to participate. The DRP has a transparent peer-reviewed selection process that incorporates defined criteria for funding decisions. We require that Developmental Research Awardees be active in SPORE functions, use the SPORE Core resource, and provide formal written progress reports. Within the context of the DRP, we have established high standards and expectations of the investigators and have established a formal process to review and monitor progress of funded pilots. The program measures success by resulting publications, resulting funding, stimulating new aims in existing SPORE projects, and elevation to new full projects for the future.
The Development Research Program of the Penn/Wistar Skin Cancer SPORE will promote translational melanoma and skin cancer research by providing a mechanism for simulating grant applications for pilot projects. The applications go through committee review and with formal procedures for monitoring progress and ensuring integrations within the SPORE.
|Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4|
|Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24|
|Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30|
|Fatkhutdinov, Nail; Sproesser, Katrin; Krepler, Clemens et al. (2016) Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res 14:767-75|
|Kumar, Vinit; Cheng, Pingyan; Condamine, Thomas et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity 44:303-15|
|Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3DÂ melanoma models. Pigment Cell Melanoma Res 29:317-28|
|Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172|
|Natale, Christopher A; Duperret, Elizabeth K; Zhang, Junqian et al. (2016) Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors. Elife 5:|
|Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602|
|Wang, Joshua X; Fukunaga-Kalabis, Mizuho; Herlyn, Meenhard (2016) Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. J Cell Commun Signal 10:191-196|
Showing the most recent 10 out of 35 publications